The Cigna Group - CIGNA GROUP

Financial Performance:

• Target long-term earnings growth of 10% to 14% annually, aiming for at least $45 in Value Per Share (VPS) by 2030.
• Specialty business represents ~37% of earnings and grows at 8% to 12%, projected to become ~40% of earnings by 2030.
• Cigna Healthcare comprises ~40% of earnings, with 55% serving complex care; Pharmacy Benefit Services (PBS) is ~23% of earnings with 70% serving complex care.
• $3 billion annual gross run-rate savings target via the "Accelerate to One" productivity initiative (70-80% from automation/process reengineering, 20-30% from vendor optimization).
• PBS margins targeted at 4% with 2027 expected to be the trough year due to headwinds.
• CVS Health split announcement noted; Cigna strategy remains unchanged, focusing on capital deployment to hit a 40% debt-to-capital ratio by end of 2026.
• Share repurchases and M&A are part of a capital allocation plan utilizing ~20-25% of $50 billion projected operating cash flow through 2030.

Guidance and Future Outlook:

• Long-term growth relies on three levers: core market growth, distinct capabilities, and execution efficiency.
• 2027 is projected as a "trough year" for PBS growth (flat to 4%), with recovery and growth expected post-2027 driven by the new "Signature" model launch.
• Specialty earnings growth is expected to moderate in 2027 (lower end of 8-12% range) compared to 2023-2026 due to smaller new drug launches, though pipeline visibility remains strong through 2030.
• Full deployment of the "Signature" PBM model is scheduled for 2028, expected to drive PBS growth beyond the 2027 trough.
• Cigna Healthcare stop-loss margins are recovering on track, with 75% of margin recapture completed by end of 2026 and remaining 25% in 2027.
• Exit from the individual exchange business is planned, which will improve overall portfolio margin despite the loss of the current low-margin book.

Business Segments and Product Lines:

• Specialty: Largest growth driver; 2023-2026 CAGR was 13%, driven by major launches (Stelara, Yamara, Revlimid generics). Future growth depends on smaller relative-sized launches but remains robust.
• PBS: Facing headwinds from reduced GLP-1 coverage in corporate plans and shrinking rebate pools (partially due to IRA drug pricing). Launching "Signature" model to offer transparent, fee-based pricing replacing the rebate model.
• Cigna Healthcare: Trending and MCR tracking expectations; 60 basis points of trend pressure attributed to the Independent Dispute Resolution (IDR) process. Success continues in the under-500 employee (select) segment.
• Evernorth: Overall earnings expected to grow low single digits in 2027. CuraScript (wholesale distribution) targets $20 billion revenue growth by 2030, leveraging Evernorth wholesale to expand direct-to-provider distribution.
• CuraScript/Acredo: Opportunities exist to expand the ecosystem, currently holding only ~7% of the $480 billion medical benefits market, with potential to cross-sell health plans via Shields investment.

Market and Competitive Landscape:

• Market shifting toward transparent PBM models; clients increasingly concerned with fiduciary responsibilities and demand for predictable per-member, per-month pricing.
• GLP-1 coverage moderation observed, with ~50% of employers covering these drugs and an expected further decline.
• CVS Health's strategic split of retail and PBM businesses acknowledged but viewed as not altering Cigna's strategic roadmap.
• Cigna emphasizes its "Lead to One" strategy and integrated ecosystem as a competitive advantage for serving complex care populations.
• Regulatory changes (IRA, IDR process) are significant market drivers affecting pricing, rebates, and trend pressures.

Risks and Challenges:

• IDR Process: Continues to create trend pressure (approx. 60 bps this year), expected to increase next year due to regulatory changes making submissions cheaper/more frequent.
• Rebate Pool Reduction: Shrinking overall rebate pools due to drug pricing laws (IRA) impacts revenue, though clients retain most of the value.
• GLP-1 Dynamics: Decreasing employer coverage for weight-loss drugs creates a near-term revenue headwind for PBS.
• Launch Volatility: Specialty business growth may fluctuate year-to-year based on the size and timing of new drug/biosimilar launches.
  Stop-Loss Recovery: While on track, the timeline for full margin recapture creates a mixed performance profile compared to normal trends.

Management Commentary and Tone:

• Tone is confident and strategic, emphasizing a deliberate portfolio shape and readiness for complex care demands.
• Management views the 10-14% growth range as a "minimum" floor if market momentum and distinct capabilities align, not a ceiling.
• Reiteration that $45 VPS by 2030 assumes zero growth in PBS, implying the business is heavily weighted on Specialty and Cigna Healthcare growth plus capital deployment.
• Management dismissed the election outcome as having no strategic impact after 234 years of operation.
• Acknowledged transition costs for the Signature rollout are incurred in 2024/2025, with no incremental costs expected in 2027.

Analyst Questions and Answers:

• Q: Long-term earnings mix by 2030? A: Specialty will grow from 37% to ~40% of earnings; the portfolio is deliberately shaped for complex care.
• Q: Dependency on market vs. outperformance? A: Growth requires hitting three levers; market momentum plus distinct capabilities provides a pathway to 10-14%.
• Q: Source and split of $3B productivity savings? A: 70-80% from automation/process, 20-30% from vendor optimization; funds will be reinvested or fall to bottom line based on ROI.
• Q: Evernorth 2027 outlook and PBS headwinds? A: PBS in "trough" due to GLP-1 coverage drop and shrinking rebates; overall Evernorth up low single digits.
• Q: Signature model adoption barriers? A: Education and benefit construction are key; clients are open to transparent fee models for fiduciary safety.
• Q: Impact of removing exchange business on MLR? A: Removing the low-margin exchange business will increase the overall portfolio MLR.
• Q: CVS split impact? A: No strategic change; Cigna's diversified portfolio remains resilient.
• Q: Timeline for buyback acceleration? A: Debt-to-cap to reach 40% by end of 2026; buybacks expected to accelerate in 2027 to meet long-term targets.

Other Key Points:

• Signature Model: A fee-based, transparent PBM model launching fully in 2028, promising lowest prices for patients and predictable costs for employers.
• Wholesale Distribution: Evernorth's integration with CuraScript aims to expand beyond health plans to direct-to-provider distribution.
• Capital Allocation: $50 billion operating cash flow projected through 2030; allocation split between organic investment, dividends, and buybacks/M&A.
• Complex Care Focus: All three main business units (Specialty, Cigna Healthcare, PBS) have majority of their earnings derived from serving complex care patients (55-70%).
• Investor Day Alignment: Call reinforced the "Accelerate to One" modernization and the 2030 targets outlined in the recent investor presentation.